SEC Form 4 · accession 0001415889-18-001033
Niagen Bioscience, Inc. · NAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert N Fried
Officer — CEO · Director
Period of report
Jun 22, 2018
Accepted (ET)
Jun 26, 2018 · 5:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001386570
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 22, 2018 | A | 166,667 | $0.00 | A | 1,093,241 | D | |
| Common StockF2 | holding | — | — | — | 12,744 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3,F4 | $3.83 | Jun 22, 2018 | A | 744,097 | A | Jun 22, 2019 | Jun 22, 2028 | Common Stock | 744,097 | 744,097 | D |
Explanation of responses
- F1These fully-vested shares are awarded to Mr. Fried pursuant to the achievement of the performance criteria detailed in his Executive Employment Agreement, dated March 12, 2017, as amended.
- F26,744 shares held by Jeremy Fried and 6,000 shares held by Benjamin Fried, who are both sons of Robert Fried.
- F3Awarded pursuant to his Amended and Restated Executive Employment Agreement dated June 22, 2018, in consideration of his appointment by the Board to CEO.
- F41/3rd of the shares vest on June 22, 2019 and the remaining shares vest in a series of 24 equal monthly installments thereafter.